Mavilque Injection (Ibandronic Acid Sodium Monohydrate)

Adult administration

3 mg is administered by intravenous injection every 3 months over 15-30 seconds.

This medication must be administered intravenously, and great care must be taken to avoid administration into an artery or around a vein, as tissue damage may occur. It should not be used in patients with a known allergy to this medication or any of its components, or in untreated hypocalcemia patients. Use of this medication may result in gastrointestinal adverse reactions such as gastritis, diarrhea, abdominal pain, indigestion, nausea, and constipation. Musculoskeletal pain, joint pain, and muscle pain may occur, and some patients may experience systemic symptoms such as influenza-like symptoms, fatigue, headache, and rash. Rarely, during the administration of this drug, allergic reactions such as vasculitis, hypersensitivity, skin rash, angioedema, and urticaria may occur, so caution is advised. Bisphosphonate medications can cause serious side effects like osteonecrosis of the jaw, so it's advisable to have a dental check-up before taking this medication and to avoid excessive dental treatment during therapy. Long-term use of this medication may lead to atypical fractures in the femur and other bones; if there is pain in the leg or groin, immediate consultation with a healthcare professional is required. This medication can temporarily lower serum calcium levels, so adequate intake of calcium and vitamin D should be ensured before and during treatment, and it should be used only after hypocalcemia is treated. Patients with poor kidney function or taking other medications that may affect the kidneys should have regular check-ups to monitor their condition. It is recommended that pregnant or breastfeeding women do not use this medication, as its safety has not been established. In case of overdose, the renal and hepatic functions may be affected; therefore, immediate monitoring and appropriate treatment at a hospital should be sought if overdose is suspected. This medication should not be mixed with calcium-containing solutions or other intravenous medications and must be administered solely via intravenous injection. After use, do not reuse the syringe or needle, and dispose of them safely, keeping them out of reach of children.

Serious side effects

Urticaria, angioedema, facial swelling/edema, hypersensitivity, anaphylactic reactions/shock, Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, vascular disorders (phlebitis/thromboangiitis), respiratory distress, skin peeling, multiple organ failure, death, acute renal failure, severe allergic reactions, severe edema or urination abnormalities

Mild side effects

• Gastritis
• diarrhea
• abdominal pain
• indigestion
• nausea
• constipation
• musculoskeletal pain
• joint pain
• muscle pain
• influenza-like illness

Store this medication in a sealed container to prevent air or moisture ingress, and it's best to keep it at room temperature between 1°C and 30°C. Proper storage can ensure the safety of the medication's efficacy.

Appearance

An injection in a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, equipped with a single-use injection needle.

Package unit

1 prefilled syringe (3mL/pre-filled syringe)